drugset / Trial / NCT01199874

Immunogenicity of Rotavirus Vaccine

NCT01199874

Phase 4 Completed 1140 enrolled PATH
RandomizedParallel-groupOpen-labelPrevention

Summary

Rotavirus is one of the most common causes of severe diarrhea, responsible for 40% of all diarrhea related deaths in children worldwide. Two vaccines against Rotavirus, Rotarix® and Rotateq® were licensed in many high and middle income countries in 2006, but lack of efficacy data in low income countries had prevented WHO from making a universal recommendation of their use until recently. This study will be conducted in Pakistan and will look at two objectives: 1. To compare the immunogenicity of Rotarix® vaccine when administered at 6 and 10 weeks of life and at 6, 10 and 14 weeks of life. 2. To compare the immunogenicity of Rotarix® vaccine in infants breast fed at the time of vaccine administration with infants whose breast feeding is withheld for one hour before and after vaccine administration.

Timeline

Start
2011-04
Primary completion
2012-09
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine 1 ml Oral

Indications